Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine
Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine.
The partnership expands Precision for Medicine’s ability to match patients who could benefit from life-saving therapies, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials. Trialbee enables accurate and fast enrollment, improving the patient journey and helping to meet patient enrollment timelines.
The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can combine with Trialbee’s targeting data to identify untapped populations for trials. This outreach, which can be geotargeted to trial candidates close to that site, greatly enhances patient enrollment with a focus on representative trial participants.
Trialbee HIVE™ is a real-world data-driven patient matching platform that accelerates recruitment using global data assets, look-alike modeling, and digital outreach. Then, interested participants are qualified and enrolled through a nurse qualification process and patient centric experience.
Both companies are industry leaders in applying technology and data science to help clinical research sponsors succeed in the development of life-changing therapies. Precision has comprehensive study experience in complex therapeutic area and a converged approach to development that includes seamless operations between labs, data, and trials.
“We are working with life science innovators who share a passion to connect next generation treatments with the patients who need them most,” said Precision for Medicine President, Chad Clark. “This partnership expands our ability to reach more patients, faster; particularly those with rare or difficult-to-treat diseases.”
Precision for Medicine and Trialbee also reduce the burden on patients and sites. Trialbee’s patient data, which is HIPPA compliant, includes socioeconomic data as well as clinical data, enabling better characterization of the patient population. This helps Precision for Medicine forecast situations in which decentralized clinical trial approaches may be implemented to accommodate work schedules or when the use of free transportation services to and from the site can increase enrollment and retention.
“Our combined capabilities support a patient-first approach that will expand diversity, bolster enrollment, and speed the development of new therapies for complex diseases,” said Trialbee’s CEO, Matt Walz. “Our ability to bring more transparency and easy communication to the well-established Precision framework improves the potential for life-saving drugs to get to market and improve patient outcomes.”
About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that integrate clinical trial execution with deep scientific knowledge, laboratory expertise and advanced data sciences. This convergence of trials, labs and data sciences is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine group with over 2,500 people in 35 locations in the U.S., Canada, and Europe. For more information, visit http://www.precisionformedicine.com.
About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Our Candidate Manager platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs and virtual/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005145/en/
Contact information
Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com
Louis Landon
Precision Medicine Group
310 984 7707
louis.landon@precisionvh.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 08:00:00 EET | Press release
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne
Leading e-wallets adopt Ant International's generative AI innovation platform to elevate customer experience14.11.2025 07:58:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has announced that it is collaborating with e-wallet operators TNG Digital, the operating company of TNG eWallet, and easypaisa, Pakistan’s first digital bank, to deliver better customer experiences with AI, supported by Ant International's AI-as-a-Service platform for fintechs and superapps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113098837/en/ Ant International’s AI-as-a-Service platform equips fintech partners with tools to build a wide range of agentic solutions, from customer-service assistants to sales copilots. Alipay+ GenAI Cockpit is an AI innovation platform designed to help financial services businesses build generative AI-driven agentic applications, backed by Ant International’s deep domain excellence in financial services, and proven know-how in helping merchants and e-wallets digitalise operations. W
The Estée Lauder Companies Makes Strategic Minority Investment in Mexican Luxury Fragrance Brand XINÚ13.11.2025 23:50:00 EET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced a minority investment in XINÚ, a Mexican luxury fragrance brand inspired by the abundance and exoticism of the American continent. This investment marks the first time The Estée Lauder Companies has invested in a Latin American brand, underscoring the company’s commitment to championing local entrepreneurship and innovation. Since its founding in 2017, XINÚ has created a distinctive universe where fragrance, design, and storytelling converge. The brand is celebrated for its sensorial retail spaces, sustainable design ethos, and products that honor heritage while reimagining modern luxury. “Fragrance excellence and craftsmanship are at the heart of The Estée Lauder Companies, and they drive our passion for discovering new voices in beauty,” said Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies. “Mexico has become a vibrant hub of fragrance innovation — a place where craftsmanship and cult
Stage Set for World’s Largest Autonomous Race as A2RL Reaches Full Fan Capacity at Yas Marina Circuit13.11.2025 20:02:00 EET | Press release
The world’s largest autonomous car race will take place in Abu Dhabi on the 15th of November, as 11 teams from across the globe compete at the frontier of robotics, autonomy and AI for a US$2.25 million prize pool. A2RL Season 2 has been 18 months in the making, with the six fastest teams making it through the tough qualification process to the Grand Final. Ticket allocation for the Yas Marina Circuit event has once again reached full capacity of the main grandstand, as motorsport and technology enthusiasts excitedly prepare to witness an AI competition unlike any other. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113967122/en/ EAV-25 autonomous racecars from finalist teams line up on the grid at Yas Marina Circuit. (Photo: AETOSWire) Grand Final: Front row seat to AI history The A2RL Grand Final will mark the first time that six fully autonomous racecars will compete wheel-to-wheel on track. The six teams – TUM, Unimo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom